← back to search

Tamara P. Miller

Emory University · US
Area of research
Public Health, Environmental and Occupational Health · Pediatrics, Perinatology and Child Health
Research interest
Research interests include Acute Lymphoblastic Leukemia research, Childhood Cancer Survivors' Quality of Life, Neutropenia and Cancer Infections, and Acute Myeloid Leukemia Research.
h-index
17
citations
1,073
works
123
NIH funding
primary concept
email

Recent publications

P-2113. Performance of a Commercial Metagenomic Microbial Cell-free DNA Sequencing Assay in Identifying Explanatory Pathogens of Pulmonary Nodules in a Multi-Center Pediatric Immunocompromised Population
Open Forum Infectious Diseases 2026cited by 0position: middledoi
633. Incidence and Outcomes of Pediatric Allogeneic Hematopoietic Cell Transplant (allo-HCT) Recipients Under Surveillance and Not Under Surveillance for Human Adenovirus (HAdV) in the Post-HCT Period
Open Forum Infectious Diseases 2025cited by 0position: middledoi
Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort
JNCI Journal of the National Cancer Institute 2025cited by 0position: middledoi
Initiation of ACE inhibitors or beta-blockers during frontline therapy for pediatric Acute Myeloid Leukemia and the impacts on cardiotoxicity incidence and survival outcomes: A target trial emulation
Blood 2025cited by 0position: middledoi
Early cardiotoxicity and survival in pediatric Acute Myeloid Leukemia: The mediating roles of relapse and salvage chemotherapy intensity
Blood 2025cited by 0position: middledoi
Real-world post-relapse survival outcomes in children with Acute Myeloid Leukemia by race and ethnicity
Blood 2025cited by 0position: middledoi
Optimization of induction chemotherapy in pediatric patients with Acute Myeloid Leukemia: Real-world evidence to support removal of etoposide from induction 1
Blood 2025cited by 0position: middledoi
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children
New England Journal of Medicine 2024cited by 159position: middledoi
Supportive Care in Pediatric Oncology: Opportunities and Future Directions
Cancers 2023cited by 26position: middledoi
Preventable harm because of outpatient medication errors among children with leukemia and lymphoma: A multisite longitudinal assessment
Cancer 2023cited by 23position: middledoi
A phase 3 trial of inotuzumab ozogamicin for high-risk B-ALL: Second safety phase results from Children’s Oncology Group AALL1732.
Journal of Clinical Oncology 2023cited by 20position: middledoi
Clinical covariates that improve the description of high dose methotrexate pharmacokinetics in a diverse population to inform MTXPK.org
Clinical and Translational Science 2023cited by 14position: middledoi
Inclusion of a core patient-reported outcomes battery in adolescent and young adult cancer clinical trials
JNCI Journal of the National Cancer Institute 2022cited by 38position: middledoi
Burkitt lymphoma after solid‐organ transplant: Treatment and outcomes in the paediatric <scp>PTLD</scp> collaborative
British Journal of Haematology 2022cited by 17position: middledoi
Multicenter study of pediatric Epstein‐Barr virus–negative monomorphic post solid organ transplant lymphoproliferative disorders
Cancer 2022cited by 12position: middledoi
Pediatric EBV-negative monomorphic post–solid organ transplant lymphoproliferative disorders [EBV(-)M-PTLD]: Characteristics, treatment, and outcome from 11 pediatric academic centers.
Journal of Clinical Oncology 2022cited by 1position: middledoi
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL: Safety Phase Results from Children's Oncology Group Protocol AALL1732
Blood 2021cited by 14position: middledoi
Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events
Pediatric Blood & Cancer 2019cited by 60position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Jeremy D. Rubinstein · University of Virginia3 papers (2022–2022)Lianna J. Marks · Palo Alto University3 papers (2022–2022)Karen M. Chisholm · Seattle Children's Hospital3 papers (2022–2022)Joanna Robles · Wake Forest University3 papers (2022–2022)Sarah McCormack · George Washington University3 papers (2022–2022)Clinton C. Mason · Huntsman Cancer Institute3 papers (2022–2022) · 3 papers (2022–2022)Holly Edington · Emory University3 papers (2022–2022)Matthew J. Ehrhardt · University of Tennessee Health Science Center3 papers (2022–2022)Maureen M. O’Brien · University of Colorado Anschutz Medical Campus3 papers (2021–2023)Zeinab Afify · University of Utah3 papers (2022–2022)Erika Friehling · UPMC Hillman Cancer Center3 papers (2022–2022) · 3 papers (2022–2022)Mansi Dalal · University of Florida3 papers (2022–2022)James B. Ford · University of Colorado Denver3 papers (2022–2022)Andrew Bukowinski · University of Alabama at Birmingham3 papers (2022–2022) · 3 papers (2022–2022)Sarah Alexander · BC Children's Hospital3 papers (2021–2023)Richard Aplenc · University College London2 papers (2019–2025)Alix E. Seif · University of Sharjah2 papers (2019–2025)